Literature DB >> 26636156

Efavirenz as a cause of ataxia in children.

M P K Hauptfleisch, D P Moore, J L Rodda.   

Abstract

Acute ataxia in childhood is often caused by toxin ingestion. With the increasing number of paediatric patients on antiretroviral medication, we observe more side-effects of these drugs. Acute ataxia is defined as unsteadiness of walking or fine motor movement of <72 hours. The most common causes are postinfectious acute cerebellar ataxia, toxin ingestion and Guillain-Barré syndrome. However, the possibility of a mass lesion must always be excluded. Reported neurological abnormalities in HIV-positive children range from 10% to 68%. A South African study found the prevalence of neurological complications to be 59%, the most common of which were HIV encephalopathy and long-tract motor signs; however, no cases of cerebellar dysfunction were documented. Ataxia rarely occurs in an HIV-positive person, the chronic sequelae being neurocognitive impairment and polyneuropathy. Ataxia in the setting of HIV is generally secondary to an infectious, vascular or neoplastic cerebellar lesion. However, most infections are opportunistic and unlikely to occur when CD4 levels are adequate. The vascular or mass lesions are readily excluded with neuro-imaging. We report 2 cases of efavirenz toxicity that caused ataxia. We treated 2 children who presented in a 1-month period, which highlighted an important differential to consider in HIV-positive paediatric patients presenting with ataxia.

Entities:  

Year:  2015        PMID: 26636156     DOI: 10.7196/samjnew.8780

Source DB:  PubMed          Journal:  S Afr Med J


  2 in total

1.  Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series.

Authors:  Ebrahim Variava; Farai R Sigauke; Jennifer Norman; Modiehi Rakgokong; Petudzai Muchichwa; Andre Mochan; Gary Maartens; Neil A Martinson
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

2.  Efavirenz-Induced Delayed Onset Cerebellar Ataxia and Encephalopathy.

Authors:  Grk Sarma; Delon Dsouza; Savitha Sebastian; Priyanka Prakash
Journal:  Ann Indian Acad Neurol       Date:  2021-06-03       Impact factor: 1.383

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.